The first child was officially enrolled in the TarGeT clinical trial, which is now open at The Royal Children’s Hospital, Melbourne and Perth Children’s Hospital, marking a significant step forward in expanding access to precision medicine for children with high-grade gliomas. We’re grateful to the family, clinicians and researchers involved, and to all those working together to improve outcomes for kids facing brain cancer.

The Robert Connor Dawes (RCD) Foundation is proud to be part of the TarGeT Collaborative, alongside Children’s Cancer Foundation, My Room Children’s Cancer Charity, The Kids’ Cancer Project, the Mark Hughes Foundation Centre for Brain Cancer Research, and The Cure Starts Now Cancer Foundation. Together, these organisations share a commitment to accelerating progress in paediatric brain cancer research through collaboration, innovation and shared purpose.

We congratulate ANZCHOG, the investigators, research teams and hospital staff whose dedication has brought TarGeT to life, and we look forward to the impact this trial will have for children and families now and into the future.

Watch the 9 News coverage below.